Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + mitoxantrone + paclitaxel + thiotepa
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A high-dose chemotherapy combination regimen consisting of melphalan, mitoxantrone, paclitaxel, and thiotepa. This regimen was studied primarily for metastatic breast cancer, administered as two cycles of melphalan, thiotepa, and paclitaxel followed by two cycles of mitoxantrone, thiotepa, and paclitaxel. Each cycle is supported with autologous peripheral blood progenitor cells to manage myelosuppression.
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNACYP2B1 (Cytochrome P450 2B1)
Beyond the preview
Go deeper on melphalan + mitoxantrone + paclitaxel + thiotepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + mitoxantrone + paclitaxel + thiotepa.